Department of Oncology, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute, 74573Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen, China.
Shantou University Medical College, Shantou, China.
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221103318. doi: 10.1177/15330338221103318.
Colorectal cancer (CRC) is associated with numerous genetic disorders and cellular abnormalities, and liver metastasis is a common health concern in patients with CRC. Exploring newer and more efficient therapies to block liver metastasis is pivotal for prolonging patient survival. Therefore, small interfering RNAs (siRNAs) are expected to be remarkable tools capable of regulating gene expression by participating in a process called RNA interference (RNAi). RNAi is a biological process among eukaryotes wherein specific messenger RNA (mRNA) molecules are destroyed and gene expression is inhibited. This technology is a promising therapeutic agent in the treatment of CRC liver metastasis (CRLM). Nevertheless, crucial problems in siRNA therapeutics, including inherent poor serum stability and nonspecific uptake into biological systems, must be recognized. For this reason, delivery systems are being developed in an attempt to solve these problems. Here, we discuss the utility of siRNA therapy for the treatment of CRCLM by targeting the major metastasis-related signaling pathways. siRNA therapy has the potential to be one of the most effective methods for CRLM treatment in the future.
结直肠癌（CRC）与许多遗传疾病和细胞异常有关，肝转移是 CRC 患者常见的健康问题。探索新的、更有效的治疗方法来阻断肝转移对于延长患者的生存至关重要。因此，小干扰 RNA（siRNA）有望成为一种通过参与称为 RNA 干扰（RNAi）的过程来调节基因表达的显著工具。RNAi 是真核生物中的一种生物学过程，在此过程中，特定的信使 RNA（mRNA）分子被破坏，基因表达被抑制。这项技术是治疗结直肠癌肝转移（CRLM）的一种很有前途的治疗药物。然而，必须认识到 siRNA 治疗中的一些关键问题，包括内在的血清稳定性差和非特异性进入生物系统。为此，正在开发输送系统以试图解决这些问题。在这里，我们讨论了通过针对主要转移相关信号通路来利用 siRNA 治疗治疗 CRCLM 的效用。siRNA 治疗有可能成为未来治疗 CRLM 的最有效方法之一。
